 |
|
|
||||||||||||||
 |
|
|
Mickey S. Urdea, Co-Founder, Chairman and Chief Executive Officer
Dr. Urdea was one of the first employees at Chiron where he directed the nucleic acids chemistry group and began the molecular diagnostics efforts. He led the development of quantitative RNA and DNA assays, including the introduction of the first HIV and HCV viral load tests. He became head of the Nucleic Acid Diagnostics business unit at Chiron. In 1998, he joined Bayer Diagnostics as Senior Vice President of Nucleic Acid Diagnostics and acting-Chief Scientific Officer of Bayer Diagnostics. He left Bayer in 2000 and co-founded Tethys Bioscience in 2002. Dr. Urdea received a Ph.D. in biochemistry at Washington State University and held an NIH postdoctoral fellowship at UCSF with William J. Rutter. He has published more than 185 articles and book chapters, and is an inventor on more than 100 issued and pending patents.
Gregory Went, Ph.D., Co-Founder
Dr. Went is currently the Chairman and CEO of Adamas Pharmaceuticals, Inc., a start-up neuropharmaceutical company focused on the development of aminoadamantanes for CNS applications. Prior to this, he co-founded and served as Executive Vice President and Director of CuraGen from 1992 to 1999. He is currently an advisor/board member to numerous companies and venture firms, including Tethys Bioscience (co founder), Angelica Therapeutics, CMEA and MDV. He received his B.S. in Chemical Engineering from Carnegie Mellon University in 1985, his Ph.D. in Chemical Engineering from UC Berkeley in 1990, and post-doctoral training at Cornell University. He is published in the fields of spectroscopy, genomics and neuroscience and is an inventor on over 40 issued and pending patents.
Bill Ericson, General Partner, MDV-Mohr Davidow Ventures
Bill Ericson joined MDV in 2000 after more than a decade of working closely with entrepreneurs to start and build innovative businesses in the role of lawyer, board member, entrepreneur and investor. Bill's investment focus at MDV is primarily in life sciences, with a current specific focus on molecular diagnostics and platforms that will enable the vision of personalized medicine. He works closely with a cross-disciplinary team of leading scientists, researchers and entrepreneurs, and seeks to apply technology solutions to life sciences in non-traditional ways. Bill has also led investments in a number of information technology and Internet companies. In addition to serving on the board of Pacific Biosciences, Bill is also on the board of Adamas Pharmaceuticals, Artemis Health, Cellpoint Diagnostics, nLight Photonics, RainDance Technologies, Revenue Science, Sabrix and Visible Measures. Prior to MDV, Bill founded and ran Venture Law Group's Seattle office. Bill is particularly proud of being a member of the founding team of Rosetta Inpharmatics and serving on its board of directors until its acquisition by Merck in 2001. Bill serves on the board of Northwestern University School of Law and is a member of the Personalized Medicine Coalition. Bill received his B.S.F.S. from Georgetown University of Foreign Service and J.D. from Northwestern University School of Law.
Brook Byers, Kleiner Perkins Caulfield & Byers
Brook Byers has been a venture capital investor at Kleiner Perkins Caufield & Byers since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients.
Lawrence B Leisure, Managing Director at Ingenix Consulting
Larry Leisure is a Managing Director at Ingenix Consulting where he leads their Payer & Employer segments.
He has had a distinguished career in healthcare serving in a number of senior consulting and industry roles. Most recently he held the role of President of iMetrikus, a leader in the broad application of biometric monitoring to population health. From 2004 to 2007 he served as a senior executive at Kaiser Foundation Health Plan where he was engaged in shaping their go to market strategy and in building a high performance sales & account management organization.
Until 2004 Larry was the Global Managing Partner, Healthcare Industry at Accenture where he was responsible for industry strategy, thought leadership and offering development and oversight. He was recruited to the organization as Managing Partner — Strategy Practice for their North American Healthcare Unit. He subsequently ran Accenture's Global Business Launch Centres, which assisted early stage companies, both venture and corporate funded, in building needed capabilities and infrastructure. During his tenure at Accenture he served as client partner for a number of the largest payers representing a number of the largest commercial, Blue Cross Blue Shield plans and PBMs.
Prior to Accenture, he held senior management roles at both Price Waterhouse and Tower Perrin. As the health benefits practice leader at Towers Perrin he was instrumental in leading a number of significant change initiatives at major Fortune 50 companies including Allied Signal, American Airlines, AT&T, Federated Department Stores, Procter & Gamble and Shell Oil.
He is well known in the industry as an innovator and thought leader credited with a number of industry innovations including the now popular health benefits offering - Point of Service plans, as well as the acceleration of adoption specialty managed care programs by major employers and payers.
He received his AB in Economics from Stanford University and his MBA in Finance from the University of California, Los Angeles.
George M. Rehm, Managing Partner of aeris CAPITAL AG.
Mr. Rehm is a managing and founding partner of aeris CAPITAL AG in Switzerland and has over twenty-five years experience as a lawyer and executive in international licensing, technology transfer, investment and privatization transactions, involving the US, Europe and Asia. Currently Mr. Rehm's focus is in private equity and he holds board seats at ViaLogy PLC, a London Stock Exchange listed company, as well as Sensovation AG, and TTTech AG, Barnev Inc. and formerly Affimed Therapeutics AG. Prior to beginning his career in private equity in 2000, Mr. Rehm was legal counsel in numerous international technology transfer transactions, including deals in China and Russia for Nutrasweet, Applied Materials, Monsanto, Spectra Physics, Dow Corning, Mitsubishi Heavy Metals, and Daewoo Electronics. He was engaged for over eight years in a law practice focusing on privatization and cross-border investment transactions in Eastern Germany, the Czech Republic and the former USSR. He also served as legislative counsel on foreign trade and European Investment to major US electronics industry associations (AEA, SEMI), providing testimony and representation to them before the US Congress. Prior to attending law school, he served as legislative assistant and speech writer to US Senator Birch E. Bayh, Jr and Hon. Lee Hamilton, MC. He also served as CEO of a European health care IT developer, which he successfully sold to Data Card Corporation. Mr. Rehm remains of counsel to the Munich, Heidelberg and Berlin law firm of Weitnauer Partners. He received his BSFS from Georgetown University, and a JD from the University of California, Hastings College of Law, completing course work in law and city planning and serving as research assistant and lecturer at the University of California-Berkeley, Boalt Hall, and the University of Maryland. Mr. Rehm has written and lectured frequently in Germany and the US on international trade, investment, technology transfer, health care, and venture capital.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)
Sep 24, 2009
A preemptive strike on diabetes: Emeryville's Tethys Biosciences rolls out pre-diabetes test
Tethys Bioscience featured in the September/October 2009 issue of Healthcare Journal of Northern California.
Aug 31, 2009
Personnel Additions and Promotions at Tethys Bioscience
Management Team in Position for Full Commercialization of its Line of Personalized-Prevention Diagnostics
Jul 15, 2009
Peer-Reviewed Publications Demonstrate Tethys Bioscience's Ability to Identify those at Highest Risk of Developing Type 2 Diabetes within Five Years
Diabetes journals publish two definitive papers supporting both the science behind and the clinical performance of lead product, the PreDx™ Diabetes Risk Score (DRS)
Jun 7, 2009
New Data in Support of Tethys Bioscience's PreDx™ Diabetes Risk Score Presented at ADA Scientific Sessions
New data support cost-effectiveness and clinical utility of a risk assessment test for type 2 diabetes